Development of active and passive human vaccines to treat methamphetamine addiction.
Development of active and passive human vaccines to treat methamphetamine addiction.
复制标题
DOI：
10.4161/hv.5.4.7456
复制
发表时间：
2009-04
期刊：
影响因子：
--
通讯作者：
Owens SM
中科院分区：
文献类型：
--
作者：
Gentry WB;Rüedi-Bettschen D;Owens SM
甲基苯丙胺（METH）滥用是一种主要的世界性流行病，没有治疗慢性或急性影响的特定药物。抗METH抗体有可能挽救生命，减少METH滥用的致残作用。虽然它们预计不会成为立即治愈成瘾的灵丹妙药，但免疫疗法可以提供一种突破性的药物，在全面的成瘾康复计划中持续阻断或减弱METH的作用。METH抗体拮抗剂的一个独特挑战是需要保护大脑免受长期使用METH的复杂的直接和间接不良反应。为了应对这一挑战，新一代被动单克隆抗体和主动免疫疗法正处于临床前开发的高级阶段。这两种疫苗都可以通过提供持久的保护免受METH的奖励和强化作用，在计划良好的人类METH成瘾恢复计划中发挥重要作用。
Methamphetamine (METH) abuse is a major worldwide epidemic, with no specific medications for treatment of chronic or acute effects. Anti-METH antibodies have the potential to save lives and reduce the crippling effects of METH abuse. While they are not expected to be the magic bullet to immediately cure addiction, immunotherapy could provide a breakthrough medication to continuously block or attenuate METH effects during a comprehensive addiction recovery plan. A unique challenge for METH antibody antagonists is the need to protect the brain from the complex direct and indirect adverse effects of long-term METH use. To meet this challenge, a new generation of passive monoclonal antibodies and active immunization therapies are at an advanced stage of preclinical development. Both of these vaccines could play an essential role in a well planned recovery program from human METH addiction by providing long-lasting protection from the rewarding and reinforcing effect of METH.